<DOC>
	<DOCNO>NCT00522639</DOCNO>
	<brief_summary>The objective study investigate evolution ofn 18F-deoxyglucose ( FDG ) uptake tumour characteristic determine plasma patient lung cancer concurrent radiotherapy chemotherapy</brief_summary>
	<brief_title>Predictive Value FDG-PET-CT Scans Patients With Lung Cancer Receiving Concurrent Chemo-Radiation</brief_title>
	<detailed_description>This translational research part aim give insight way radiation injury tumour response develop . It involve three part : 1 . Repetitive FDG-PET-CT scan order assess early tumour response monitoring . 2 . Blood sampling , radiotherapy order find predictor normal tissue injury tumour response . 3 . Extra stain tumour biopsy The FDG-PET-CT scan i.v . contrast give information tumour metabolism morphology . Therefore , one extra FDG-PET-CT scan do radiotherapy day 8 . Tumour response determine FDG-PET-CT scan 3 month radiotherapy . Blood sample 1 . Before radiotherapy , 12 millilitre blood ( EDTA tube ) take accord serum protocol ( appendix 5 ) . 2 . At day 7 , day 14 concurrent chemo-radiation , 7 day end treatment 3 month 9 month end radiotherapy , 12 millilitre serum ( EDTA tube ) take investigate evolution protein [ In first place , plasma concentration osteopontin soluble CA9 hypoxia , CRP IL-6 inflammation , total free VEGF angiogenesis total cleave cytokeratin 18 necrosis/apoptosis determine ] treatment , kinetics may important predictive factor . Standard ELISA test use determine level . 3 . Before radiotherapy , day 7 day 14 radiation , 7 day end treatment 3 month 9 month end radiotherapy , 24 millilitre blood ( EDTA tube ) take investigate evolution circulate cell progenitor treatment . The tumour biopsy may stain marker proliferation ( e.g . KI 67 ) , apoptosis ( e.g . M30 ) , hypoxia ( e.g . CA 9 , Glut 1 3 ) others ( e.g . EGFR EGFRvIII ) , order correlate measurement response .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Deoxyglucose</mesh_term>
	<criteria>Histological proven nonsmall cell small cell lung cancer UICC stage IIII ( case small cell lung cancer : limited stage ) WHO performance status 02 Less 10 % weight loss last 6 month In case previous chemotherapy , concurrent chemoradiotherapy start minimum 21 day last chemotherapy course No recent ( &lt; 3 month ) severe cardiac disease ( arrhythmia , congestive heart failure , infarction ) No active peptic oesophagitis Life expectancy 6 month Measurable cancer Willing able comply study prescription 18 year old Not pregnant willing take adequate contraceptive measure study Have give write informed consent patient registration No previous radiotherapy chest Not nonsmall cell small cell histology , e.g . mesothelioma , lymphoma Malignant pleural pericardial effusion History prior chest radiotherapy Recent ( &lt; 3 month ) myocardial infarction Uncontrolled infectious disease Distant metastases ( stage IV ) Patients active peptic oesophagitis last year Less 18 year old Pregnant willing take adequate contraceptive measure study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>lung cancer</keyword>
	<keyword>FDG-PET-CT</keyword>
	<keyword>blood protein</keyword>
	<keyword>prognose</keyword>
</DOC>